Mr Brian Birch

Brian Robert Peter Birch Academic Qualifications ·         1976 BA Natural Sciences, University of Cambridge, First Class Honours ·         1976 Scholar St Catharine’s College, University of Cambridge ·         1980 MB BChir University of Cambridge ·         1985 Fellow of the Royal College of Surgeons of England (England) ·         1995 MD (Cantab) National Research Ethics Service (NRES) ·         Expert member Local Research Ethics Committee (Hampshire B NRES committee)         2008 - 2015 ·               Vice Chair Local Research Ethics Committee (Southampton B NRES committee)            2021 onwards Service Development Local ·         Contributor to Map of Medicine for urology topics (e.g. haematuria, stones, UTI, prostate infection, acute urinary retention, erectile dysfunction etc.) ·         Member Chronic and Recurrent Abdominal Pain Steering Group (2016 to date) National ·         Contributor to NHS Choices Patient Information, NHS Research Priorities and the NHS Clinical Knowledge ·         Contributor to NIHR Health Technology Assessment (HTA) program Evaluation, Trials and Study co-ordinating centre: ·         110761 NIHR Health Technology Assessment 11/142  Photodynamic guided treatment for bladder cancer 12 Dec 2012 ·         110761 NIHR Health Technology Assessment 11/142  Photodynamic guided treatment for bladder cancer 23 Jan 2013 ·         124842 NIHR Health Technology Assessment 16/167 HIVEC III: A randomised controlled trial comparing adjuvant recirculated hyperthermic intravesical chemotherapy (HIVEC™) with mitomycin C (MMC) vs Bacillus Calmette Guérin (BCG) in high risk non muscle invasive bladder cancer (HRNMIBC) 04 Aug 2017 ·         11/142/02 PHOTOdynamic versus white light-guided treatment of non-muscle invasive bladder cancer: a randomised trial of clinical and cost-effectiveness (the PHOTO RCT) 19 March 2021 ·         14/08/60 BladderPath: Image Directed Redesign of Bladder Cancer Treatment Pathways 25 April 2021 ·         160459 NIHR Health Technology Assessment Combination chemotherapy versus Bacillus Calmette-Guérin (BCG) for high-risk non-muscle invasive bladder cancer– a phase III multi-centre randomised controlled trial (COBRA) 14 Jan 2024

These include: 1. Benign prostate disease: Urinary symptoms, prostate surgery, chronic prostatitis 2. Female urological dysfunction: Recurrent UTI, interstitial cystitis 3. Prostate cancer 4. Bladder cancer 5. Chronic pain in urology: interstitial cystitis, chronic prostatitis, Painful bladder syndrome, chronic pelvic pain syndrome, testicular pain 6: Andrology: vasectomy, testosterone replacement therapy